Background
The secretion of interferon- (IFN-) by activated immune cells is one of the hallmarks of response to cancer immunotherapy. Hence, detection of this cytokine via imaging can help determine an activated antitumor immune response. We have prev…
Background
Neoadjuvant chemoimmunotherapy (NACI) has shown promising results in treating esophageal squamous cell carcinoma (ESCC), yet the mechanisms driving its efficacy remain poorly defined, limiting further optimization of this regimen.
Methods
…
Background
Despite its viral etiology and immunogenic features, cervical cancer shows limited and often short-lived benefit from programmed cell death protein 1 blockade, currently the only approved immunotherapy for this disease. This limitation high…
Background
Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet resistance—both primary and acquired—remains a significant obstacle, affecting the majority of patients.
Methods
Here, we leverage a large-scale, real-worl…
Purpose
Aberrant alternative splicing (AS) events have been implicated in cancer progression; however, their role in metastatic renal cell carcinoma (mRCC) remains underexplored. This study aims to identify AS events associated with clinical benefits …
Background
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide. While immune checkpoint blockade has revolutionized the treatment of many cancers, responses in HCC remain limited. Robust functional platforms capable of…
Background
Advanced gastric cancer (aGC) exhibits substantial heterogeneity in response to combination immunotherapy. Circulating cell-free DNA (cfDNA) enables non-invasive profiling of tumor dynamics and may provide biomarkers for response prediction…
Background
Atezolizumab plus bevacizumab (Atez/Bev) has become the first-line therapy for unresectable hepatocellular carcinoma (HCC). However, reliable biomarkers to predict therapeutic response remain lacking.
Methods
We conducted a high-throughput…
Tumor mutational burden (TMB) and PD-L1 are established biomarkers for guiding immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC). As ICI use expands into early-stage disease, we explored the feasibility of using …
Background
Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) improve outcomes in advanced hepatocellular carcinoma (HCC), yet systemic immune mechanisms underlying response remain i…
